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INTRODUCTION
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness 
caused by novel coronavirus SARS-CoV-2. This enveloped virus has 
positive-sense RNA and belongs to the Coronaviridae family. On 12 
January 2020, the World Health Organization (WHO) named this new 
virus the “2019-novel coronavirus” (2019-nCoV).1 The primary cases in 
Iran were reported in Qom in February 2020, and shortly, positive cases 
increased rapidly everywhere in Iran.2 The clinical manifestations of this 
infection have a good range and typically include impairment of smell, 
taste disturbance, cough, fever, and shortness of breath.3 There has been 
a growing appreciation of the importance of digestive symptoms (nausea, 
vomiting, anorexia, non-bloody diarrhea, and abdominal pain) within the 
spectrum of COVID-19 disease. Also, abnormalities in coagulation 
markers have been reported in patients hospitalized with COVID-19.4 Co-
agulopathy is one of the foremost significant prognostic factors in patients 
with COVID-19 and is related to increased mortality and admission to crit-
ical care.5 In severe cases of COVID-19, SARS-CoV-2 induces a cytokine 
storm that ultimately leads to impaired pulmonary gas exchange and acti-
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Case Report
ABSTRACT
Coronavirus disease 2019 (COVID-19) is an acute respiratory illness caused by novel coronavirus 
SARS-CoV-2. The clinical manifestations of this infection have a range and typically include 
impairment of smell, taste disturbance, cough, fever, and shortness of breath. Gastrointestinal 
manifestations have been reported in anywhere from 3% to 50% of patients with concomitant 
SARS-CoV-2 pulmonary infection. Abnormalities in coagulation markers have been reported in 
patients hospitalized with COVID-19. During this article, we will introduce a patient with COVID 
19 but with the most manifestation of abdominal pain due to intestinal ischemia and mesenteric 
vascular thrombosis.
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vation of the coagulation cascade, causing thrombotic 
manifestations 6 and median plasma concentrations 
of tissue factor and plasminogen activator inhibitor-1 
(PAI-1) reported to be significantly higher in patients 
withAcute respiratory distress syndrome (ARDS) 
(at 7 days) compared with patients without ARDS 
(data not from COVID-19 patients).7 These and other 
changes increase coagulation status in patients with 
COVID 19.
The current concept of hypercoagulative states is 
supported by autopsies that have demonstrated small 
fibrinous thrombi in small pulmonary arterioles in areas 
of both damaged and more preserved lung parenchyma 
in 8 out of 10 cases.8 Furthermore,the indication of 
coagulation activation due to infection/sepsis is cytokine 
storm, and imminent organ failure.9
In this article, we will introduce a patient who 
suffered from intestinal ischemia due to COVID 19 
caused by acute mesenteric ischemia and had 
presented with abdominal pain and no initial 
pulmonary symptoms. To our knowledge, this is the 
first patient to be identified with this manifestation of 
COVID 19.
CASE REPORT
A 51-year-old male non-smoker was referred to 
the emergency room (ER) with the complaint of 
abdominal pain 3 days earlier,which she rated an 
“8” on a scale of 1 to 10 without any medical history 
and drug history. He stated that the pain worsened 
with movement and change in position. He denied 
any significant family history of the disease. During 
the physical examination, the patient was diaphoretic, 
uncomfortable, and in severe distress. His vital 
signs were: blood pressure, 156/87 mm Hg; respiratory 
rate, 19 breaths/minute; heart rate, 132 beats/minute; 
and temperature within normal limits. Oxygen 
saturation was 93% on room air. The abdominal 
examination revealed a distended abdomen that 
was severely tender to palpation. Intravenous (IV) 
fluids were immediately started for the patient. He 
was also given IV ondansetron for nausea. His pain 
was refractory to treatment and required multiple 
doses of morphine sulfate. Laboratory evaluation re-
vealed leukocytosis with a white blood cell (WBC) 
count of 14.5 thou/cm. He underwent laparotomy 
due to tenderness in favor of acute abdominal pain. 
During laparotomy, not only the small and large 
intestine but also their vasculature was normal. 
After two days, the patient was discharged with no 
pain and symptom. With nausea, abdominal pain, 
and dyspnea, he came back to the ER again after 3 
days. On examination, he had tachypnea (RR: 40/
min), tachycardia (HR: 120/min), low-grade fever 
(Temp: 38°centigrade). A lung computed tomog-
raphy (CT) (Figure 1) and an abdominopelvic CT 
(Figure 2) were done. The patient was intubated due 
to respiratory failure. Covid-19 RT-PCR (Everse 
transcription polymerase chain reaction) was per-
formed. Lab data included complete blood count 
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Fig.1: Spiral computed tomogram of the 
lung (without contrast).
Fig.2: Spiral computed tomogram of abdomi-
nopelvic (without contrast). Evidence of dilation 
in small bowel loops filled by fluid suggests an 
obstructive syndrome or ileus.
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(CBC)(WBC:17000 per microliter, Hb:12:8.7 g/
dL, Plt: 350,000 per microliter), urea :170 mg/dL, 
(creatinine) Cr:4.2 mg/dL, (Lactate dehydrogenase) 
LDH:504 U/L, (C-reactive protein) CRP:47mg/L, 
and negative viral disease (HCV Ab-hepatitis C vi-
rus antibody, HBS Ag-Hepatitis B Antigen,, HIV 
Ab (human immunodeficiency virus)The patient 
was treated with 400 mg single-dose, hydroxychloro-
quine sulfate, lopinavir/ritonavir 100/400mg twice 
daily for five days, ribavirin 1200 mg twice daily for 
five days, and three doses of 250 μg β interferon (Ev-
ery other day).
During ICU admission, on the third day, fecaloid 
discharged from abdominal suture appeared, and 
therefore the patient was on sepsis phase. Labora-
tory data were CBC (WBC: 24000 per microliter, 
Hb: 12 g/dL, Plt: 347000 per microliter), urea: 206 
mg/dL, Cr: 3.2 mg/dL,and amylase: 67 U/L.
Re-laparotomy was performed, and after laparotomy, 
serosanguinous secretions with necrotic changes in the 
small intestine were seen, so 130 cm of it was resected 
(Figure 3). The day after, due to suspicion of leakage 
from the anastomosis site, laparotomy was performed 
again and due to leakage from the anastomosis site and 
smaller bowel necrosis,100 cm of intestine was resect-
ed so ileostomy was performed. A pathological study 
(Figures 4,5) reported intravascular thrombosis in mes-
enteric tissue with a necrotic margin. The RT-PCR of 
covid-19 was reported positive.
The patient was treated with heparin infusion and 
broad-spectrum antibiotics. After 10 days of treatment 
in ICU, he was extubated, and his hemodynamic 
was stable, but platelet count began to decrease 
(162,000 per microliter), and therefore the day 
after gastrointestinal bleeding happened.
Lab test were CBC (WBC: 7100 per microliter, 
Hb: 8.7 g/dL, plt: 162000 per microliter), Cr: 1.3 
mg/dL, amylase: 65 U/L.  Plt and Cr decreased to 
69000 per microliter and 1.1 mg/dL, respectively, 
but other coagulation tests (PT and PTT) were normal 
the day after. Heparin infusion was discontinued. 
Other laboratory tests were D-dimer: 2500 ng/mL, 
fibrinogen: 150 mg/dL, PT: 44 sec, PTT: 44 sec, 
INR: 1.7. No schistocyte in peripheral blood smear 
was found. Unfortunately, the patient eventually 
developed treatment-resistant sepsis, DIC, and died 
of its complications. 
DISCUSSION
There has been a growing appreciation of the importance 
of digestive symptoms (nausea, vomiting, anorexia, 
non-bloody diarrhea, and abdominal pain) within the spec-
trum of COVID-19 disease. Presumed gastrointestinal 
manifestations have been reported anywhere from 3% 
to 50% of patients with concomitant SARS-CoV-2 pul-
monary infection.10 SARS-CoV-2 RNA has been found 
in fecal samples of patients with COVID-19 pulmonary 
disease, and initial case series have noted that 3-10% of 
patients who are eventually found to have SARS- CoV-2 
pulmonary infection were initially presented with isolated 
digestive symptoms.10
However, in some cases,the explanation for the 
gastrointestinal symptoms could also be important 
causes, the shortage of specific treatment of which is 
fatal.For instance, Alexandre Carballo and colleagues 
presented a case of SARS-CoV-2 gastrointestinal infection 
causing acute hemorrhagic colitis and signaling COVID-19 
disease.11
And in this article, we introduced a patient who suffered 
from intestinal ischemia due to COVID 19 caused by 
mesenteric vascular thrombosis.
Acute mesenteric ischemia may be a rare disorder 
defined because of the sudden disruption of the blood 
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Fig.3: Gross and microscopic view of the small 
intestine. Perforated and gangrenous small 
bowel.
Section of the perforated site and necrotic areas 
show extensive mucosal infarction and full-
thickness necrosis. Fibrin thrombi present in a 
few small to medium-sized vessels in these areas.
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supply to the intestine.12 If left untreated, it will cause 
complications and irreversible consequences like necrosis 
of the intestinal wall and death.13 We distinguished occlu-
sive and non-exclusive types of acute ischemia of the bowel 
mesentery supported their cause.14 Occlusive causes of acute 
mesenteric ischemia include mesenteric artery embolism 
(50% of cases), mesenteric artery thrombosis (15-25%), and 
celiac vein thrombosis (5-15%).15
In our opinion, the patient had increased coagulation 
and mesenteric vascular thrombosis due to COVID-19. 
There are several reasons why the hypercoagulable state 
increases in patients with COVID-19 disease. For example, 
the direct effects of COVID-19 or the indirect effects of 
infection, like through severe illness and hypoxia, may 
predispose patients to thrombotic events. Preliminary 
reports suggest that hemostatic abnormalities, including 
disseminated intravascular coagulation (DIC), occur in 
patients suffering from COVID-19.16 Additionally, the 
severe inflammatory response, critical illness, and 
underlying traditional risk factors may all predispose 
to thrombotic events, indicate thatcoagulation activation 
due to infection/sepsis, cytokine storm, and imminent 
organ failure. Studies have shown higher D-dimer level, 
fibrin degradation product, and prolonged PT on admission 
correlated with decreased survival in patients hospitalized 
for COVID-19 pneumonia, with 71.4% of patients who 
died developed overt DIC 17 and in the 18% of patients 
admitted to ICU for COVID-19-associated acute respiratory 
distress syndrome (ARDS) thrombotic complications were 
happened.despite anticoagulation therapy, in 16.7%; 
COVID-19-related to ARDS associated withPE increased 
thrombotic complications, especially compared to non-
COVID-19-associated ARDS.18
However, the important thing is thatCOVID-19 
may predispose patients to both venous and arterial 
thromboembolic disease due to excessive inflammation, 
hypoxia, immobilization, and disseminated intravascular 
coagulation (DIC).19
Patients with COVID 19 are reported to have vascular 
events; for example, Avila and co-workers reported four 
patients presenting with imaging that confirmed acute 
strokes and PCR results that confirmed SARS-CoV-2 
infection.20
Coagulopathy, antiphospholipid antibodies, and multiple 
cerebral infarctions were detected in two men (69 and 
70 years old) and one woman (65 years old) admitted 
to ICU for COVID-19 in a case series.21 Our patient had 
mesenteric vascular thrombosis and suffered from small 
bowel ischemia. In our review, this is the first report of 
this demonstration.
CONCLUSION
Abdominal pain is seen in some patients with COVID-19 
and is mostly diagnosed as a gastrointestinal manifestation 
of this infection, but the important point is that the cause of 
this abdominal pain may be other important reasons, and the 
delay in specific treatment is fatal.
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Fig.4 & 5: Intravascular thrombosis in mesenteric tissue biopsies of small bowel of the patient
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